Affiliation:
1. Data Science Astellas Pharma Global Development, Inc. Northbrook Illinois USA
2. Data Science Astellas Pharma China Beijing China
Abstract
AbstractThe primary objective of an oncology dose‐finding trial for novel therapies, such as molecularly targeted agents and immune‐oncology therapies, is to identify the optimal dose (OD) that is tolerable and therapeutically beneficial for subjects in subsequent clinical trials. Pharmacokinetic (PK) information is considered an appropriate indicator for evaluating the level of drug intervention in humans from a pharmacological perspective. Several novel anticancer agents have been shown to have significant exposure‐efficacy relationships, and some PK information has been considered an important predictor of efficacy. This paper proposes a Bayesian optimal interval design for dose optimization with a randomization scheme based on PK outcomes in oncology. A simulation study shows that the proposed design has advantages compared to the other designs in the percentage of correct OD selection and the average number of patients allocated to OD in various realistic settings.
Subject
Pharmacology (medical),Pharmacology,Statistics and Probability